PMID- 25538335
OWN - NLM
STAT- MEDLINE
DCOM- 20150831
LR  - 20181113
IS  - 1998-3751 (Electronic)
IS  - 0253-7613 (Print)
IS  - 0253-7613 (Linking)
VI  - 46
IP  - 6
DP  - 2014 Nov-Dec
TI  - Effect of coenzyme Q10 alone and its combination with metformin on 
      streptozotocin-nicotinamide-induced diabetic nephropathy in rats.
PG  - 627-32
LID - 10.4103/0253-7613.144924 [doi]
AB  - OBJECTIVES: This study was aimed to investigate the therapeutic potential of 
      coenzyme Q10 and its combination with metformin on streptozotocin 
      (STZ)-nicotinamide-induced diabetic nephropathy (DN). MATERIALS AND METHODS: Type 
      2 diabetes in rats was induced with STZ-nicotinamide. The diabetic rats were 
      treated with coenzyme Q10 (10 mg/kg, p.o.) alone or coenzyme Q10 + metformin. 
      Various parameters of renal function tests such as serum creatinine, urea, uric 
      acid, and markers of oxidative stress such as renal malondialdehyde (MDA) level, 
      superoxide dismutase (SOD), and catalase (CAT) activities were measured. Tumor 
      necrosis factor-alpha (TNF-alpha), myeloperoxidase (MPO) activity, transforming growth 
      factor-beta (TGF-beta), and nitrite content were estimated in renal tissues. All 
      treated animal were subjected to histopathological changes of kidney. RESULT: 
      Diabetic rats showed a significant reduction in renal function, which was 
      reflected with an increase in serum urea, serum creatinine, uric acid. In 
      addition, STZ-nicotinamide caused renal tubular damage with a higher MDA level, 
      depletion of SOD and CAT activity and glutathione (GSH) level. Moreover, TNF-alpha, 
      MPO activity, TGF-beta, and nitrite content were significantly increased in diabetic 
      rats, while treatment with coenzyme Q10 or metformin or their combination 
      ameliorate STZ-nicotinamide induced renal damage due to improvement in renal 
      function, oxidative stress, suppression of TNF-alpha, MPO activity, TGF-beta and nitrite 
      content along with histopathological changes. CONCLUSIONS: This finding suggests 
      that the treatment with coenzyme Q10 or metformin showed significant 
      renoprotective effect against STZ-nicotinamide-induced DN. However, concomitant 
      administration of both showed a better renoprotective effect than coenzyme Q10 or 
      metformin alone treatment.
FAU - Maheshwari, Rajesh A
AU  - Maheshwari RA
AD  - Department of Pharmacy, Sumandeep Vidyapeeth, Piparia, Vadodara, Gujarat, India.
FAU - Balaraman, R
AU  - Balaraman R
AD  - Department of Pharmacy, Sumandeep Vidyapeeth, Piparia, Vadodara, Gujarat, India.
FAU - Sen, Ashim K
AU  - Sen AK
AD  - Department of Pharmacy, Sumandeep Vidyapeeth, Piparia, Vadodara, Gujarat, India.
FAU - Seth, A K
AU  - Seth AK
AD  - Department of Pharmacy, Sumandeep Vidyapeeth, Piparia, Vadodara, Gujarat, India.
LA  - eng
PT  - Journal Article
PL  - India
TA  - Indian J Pharmacol
JT  - Indian journal of pharmacology
JID - 7902477
RN  - 0 (Hemoglobins)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Nitrites)
RN  - 0 (Protective Agents)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 1339-63-5 (Ubiquinone)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 268B43MJ25 (Uric Acid)
RN  - 5W494URQ81 (Streptozocin)
RN  - 8W8T17847W (Urea)
RN  - 9100L32L2N (Metformin)
RN  - AYI8EX34EU (Creatinine)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EJ27X76M46 (coenzyme Q10)
SB  - IM
MH  - Animals
MH  - Creatinine/blood
MH  - Diabetes Mellitus, Experimental/*drug therapy/metabolism/pathology
MH  - Diabetic Nephropathies/*drug therapy/metabolism/pathology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Hemoglobins/analysis
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Kidney/drug effects/metabolism/pathology
MH  - Male
MH  - Metformin/pharmacology/*therapeutic use
MH  - Niacinamide
MH  - Nitrites/metabolism
MH  - Peroxidase/metabolism
MH  - Protective Agents/pharmacology/*therapeutic use
MH  - Rats, Wistar
MH  - Streptozocin
MH  - Transforming Growth Factor beta/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Ubiquinone/*analogs & derivatives/pharmacology/therapeutic use
MH  - Urea/blood
MH  - Uric Acid/blood
PMC - PMC4264079
OTO - NOTNLM
OT  - Coenzyme Q10
OT  - diabetic nephropathy
OT  - metformin
OT  - transforming growth factor-beta
OT  - tumor necrosis factor-alpha
COIS- Conflict of Interest: No.
EDAT- 2014/12/30 06:00
MHDA- 2015/09/01 06:00
PMCR- 2014/11/01
CRDT- 2014/12/25 06:00
PHST- 2014/06/09 00:00 [received]
PHST- 2014/08/24 00:00 [revised]
PHST- 2014/10/21 00:00 [accepted]
PHST- 2014/12/25 06:00 [entrez]
PHST- 2014/12/30 06:00 [pubmed]
PHST- 2015/09/01 06:00 [medline]
PHST- 2014/11/01 00:00 [pmc-release]
AID - IJPharm-46-627 [pii]
AID - 10.4103/0253-7613.144924 [doi]
PST - ppublish
SO  - Indian J Pharmacol. 2014 Nov-Dec;46(6):627-32. doi: 10.4103/0253-7613.144924.